Peripheral Liquid Embolic Agent Market (2026 - 2036)

Peripheral Liquid Embolic Agent Market Summary

The global peripheral liquid embolic agent market size was valued at USD 275.6 million in 2025 and is projected to grow from USD 298.0 million in 2026 to USD 568.9 million by 2036, at a CAGR of 6.7% from 2026 to 2036. North America dominated the market, accounting for a revenue share of 39.3% in 2025. Demand for peripheral liquid embolic agents is supported by the increasing adoption of minimally invasive endovascular procedures, advancements in catheter-based embolization techniques, and the expanding use of embolization in managing peripheral vascular conditions.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

Healthcare providers are focusing on endovascular treatment options that support precise vessel occlusion, controlled embolic delivery, reduced procedural invasiveness, and effective management of vascular abnormalities. Manufacturers are also developing liquid embolic formulations with improved deliverability, radiopacity, polymerization control, and predictable occlusion characteristics to support procedural outcomes.

The rising burden of peripheral vascular disorders is a major driver of demand for peripheral liquid embolic agents. Peripheral vascular hemorrhage, arteriovenous malformations (AVMs), aneurysms, and other vascular abnormalities are becoming more prevalent due to population aging and the increasing incidence of diabetes, hypertension, smoking, and hyperlipidemia.

As the number of patients with peripheral vascular diseases continues to rise, healthcare providers are adopting minimally invasive embolization procedures to control hemorrhage, treat vascular malformations, and manage complex peripheral lesions. Liquid embolic agents provide precise, durable vessel occlusion, particularly in tortuous or distal vasculature, where conventional embolic materials are less effective.

The rising incidence of postpartum hemorrhage is increasing the demand for uterine artery embolization (UAE) as a minimally invasive, uterus-preserving treatment for uncontrolled obstetric bleeding. This growing adoption of the UAE is driving the use of peripheral liquid embolic agents, which provide rapid, targeted vascular occlusion to achieve effective hemostasis while reducing the need for emergency hysterectomy.

Source: NIH 2025

Varicose veins are among the most common chronic venous disorders, with their prevalence increasing due to aging populations, obesity, prolonged standing, pregnancy, and sedentary lifestyles. The growing preference for minimally invasive endovascular treatments is accelerating the use of embolization procedures in venous disease management.

According to INVAMED, varicose veins affect up to 30% of the general population worldwide, while the prevalence of chronic venous disorders, including spider and reticular veins, can reach 80% in men and 85% in women. This expanding patient population is driving demand for peripheral liquid embolic agents, which are used for targeted vein occlusion and other venous embolization procedures.

Portal vein embolization (PVE) is a minimally invasive interventional radiology procedure performed before major liver resection to redirect blood flow and stimulate hypertrophy of the future liver remnant, enabling safer surgical removal of liver tumors. The rising incidence of primary liver cancer and metastatic liver tumors is increasing the use of PVE as part of preoperative treatment planning, thereby driving demand for peripheral liquid embolic agents, which are widely used to achieve effective and durable portal vein occlusion during the procedure.

Estimated New Cases and Deaths from Liver and Intrahepatic Bile Duct Cancer by Sex (U.S., 2025)

Source: American Cancer Society

The increasing global burden of cancer is significantly driving the demand for interventional oncology, where minimally invasive embolization procedures are widely used to treat hyper vascular tumors and manage cancer-related complications. Peripheral liquid embolic agents enable precise occlusion of tumor-feeding vessels, making them valuable for preoperative devascularization, palliative embolization, and hemorrhage control in tumors of the liver, kidneys, pelvis, bones, and other peripheral organs.

Continuous advancements in image-guided interventions and embolic materials have further expanded the role of liquid embolic agents in oncology by improving procedural accuracy and reducing complications. Compared with conventional surgery, endovascular embolization offers shorter recovery times, lower procedural morbidity, and the ability to treat patients who are poor surgical candidates, leading to increasing adoption across interventional radiology and comprehensive cancer centers.

According to the American Cancer Society, an estimated 42,240 new cases of primary liver and intrahepatic bile duct cancer are expected to be diagnosed in the U.S. in 2025, and approximately 30,090 people are projected to die from the disease, highlighting the growing need for effective treatment approaches, including interventional oncology procedures such as trans arterial embolization.

Source: American Cancer Society 2026

Market Dynamics

The peripheral liquid embolic agent market is shaped by the increasing adoption of minimally invasive endovascular procedures, advancements in embolization techniques, and the growing use of catheter-based interventions for managing peripheral vascular conditions. Hospitals, ambulatory surgical centers, and specialty vascular centers are incorporating embolization procedures into clinical practice to manage conditions such as peripheral arteriovenous malformations, vascular tumors, and hemorrhage associated with peripheral vascular abnormalities. The demand for liquid embolic agents is also supported by the need for precise vessel occlusion, controlled embolic delivery, and reduced procedural invasiveness. Manufacturers are focusing on developing advanced formulations with improved radiopacity, catheter compatibility, polymerization control, and predictable occlusion characteristics to address evolving clinical requirements in peripheral vascular interventions.

 

Market Concentration & Characteristics

The peripheral liquid embolic agent market comprises a range of products formulated to support vessel occlusion during minimally invasive endovascular procedures for peripheral vascular conditions. The market includes cyanoacrylate-based embolic agents, ethylene-vinyl alcohol (EVOH)-based agents, and other liquid embolic formulations, with product selection varying according to the target vascular anatomy, clinical indication, and procedural requirements. Manufacturers differentiate their products through formulation composition, viscosity, radiopacity, polymerization characteristics, catheter compatibility, and delivery control. Factors such as embolization precision, occlusion effectiveness, biocompatibility, handling characteristics, and procedural safety influence product selection and purchasing decisions.

The peripheral liquid embolic agent market demonstrates ongoing product innovation, with manufacturers focusing on improving embolic formulation characteristics, delivery precision, catheter compatibility, and controlled vessel occlusion. Innovation includes the development of liquid embolic agents with enhanced radiopacity, optimized viscosity, improved polymerization control, and predictable penetration into targeted peripheral vascular structures. Manufacturers are also advancing delivery systems and formulation technologies to improve handling characteristics, reduce catheter-related complications, and support procedural accuracy. Research and development activities are directed toward improving biocompatibility, embolization consistency, and product performance across different peripheral vascular indications.

• In July 2025, Medtronic announced the enrollment of the first patient in the Peripheral Onyx Liquid Embolic (PELE) clinical trial, which is evaluating the safety and effectiveness of the Onyx Liquid Embolic System (LES) for the embolization of arterial hemorrhage in the peripheral vasculature. The first procedure was performed by Dr. Christopher Stark at Albany Medical Center.

Mergers and acquisitions in the peripheral liquid embolic agent market support portfolio expansion, access to complementary embolization technologies, and broader penetration of peripheral vascular intervention markets. Companies are pursuing strategic acquisitions to strengthen their capabilities in liquid embolic formulations, catheter-based delivery systems, and minimally invasive vascular therapies. These activities also facilitate entry into adjacent peripheral intervention segments and expand access to hospitals, specialty vascular centers, and interventional radiology facilities. Acquiring companies can strengthen research and development capabilities, manufacturing capacity, intellectual property portfolios, and distribution networks while expanding their presence across peripheral vascular treatment applications.

The peripheral liquid embolic agent market is shaped by stringent regulatory requirements governing the development, clinical evaluation, manufacturing, marketing, and post-market surveillance of embolic products. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), alongside national medical device regulators, establish requirements for product safety, biocompatibility, performance validation, quality management, and clinical evidence. Compliance with medical device regulations, including the U.S. FDA approval or clearance pathways and the European Union Medical Device Regulation (MDR 2017/745), affects product commercialization timelines, development costs, and market entry strategies. These requirements also encourage manufacturers to invest in product validation, manufacturing quality systems, and post-market monitoring to maintain regulatory compliance and clinical safety.

The peripheral liquid embolic agent market is primarily supported by hospitals, ambulatory surgical centers, and specialty vascular centers that perform minimally invasive peripheral embolization procedures. Hospitals account for a significant share of product utilization due to their advanced interventional radiology facilities, availability of specialized clinical teams, and capacity to manage complex peripheral vascular conditions. Ambulatory surgical centers are incorporating catheter-based embolization procedures into outpatient treatment settings, supporting demand for liquid embolic agents. Purchasing decisions across end users depend on procedural volumes, clinical requirements, physician preferences, product availability, and institutional procurement budgets.

Analyst Perspective

The peripheral liquid embolic agent market is competitive, with manufacturers differentiated by embolic formulation, product composition, delivery precision, radiopacity, polymerization characteristics, catheter compatibility, and clinical evidence. Established companies such as Medtronic, Terumo Medical Corporation (MicroVention), Boston Scientific, B. Braun, and Johnson & Johnson compete through their interventional product portfolios, embolization technologies, established distribution networks, and relationships with healthcare providers. Companies also differentiate through the development of EVOH-based agents, cyanoacrylate-based adhesives, and advanced delivery systems designed to support controlled vessel occlusion across peripheral vascular applications.

Product Insights

'By product, the ethylene vinyl alcohol copolymer (EVOH) segment led the market with the largest revenue share of 44.1% in 2025.' Its dominance is supported by its established use in minimally invasive embolization procedures for peripheral vascular conditions. EVOH-based agents offer controlled precipitation, radiopacity when combined with contrast agents, and the ability to form stable occlusive structures within targeted vessels. Their controlled delivery characteristics and suitability for treating complex peripheral vascular abnormalities support adoption among interventional radiologists and vascular specialists.

The cyanoacrylates/tissue glues segment is expected to register significant growth in the peripheral liquid embolic agent market, driven by their rapid polymerization, strong adhesive properties, and effectiveness in achieving immediate vessel occlusion. These agents are used in peripheral embolization procedures requiring prompt control of blood flow, including the management of vascular malformations, hemorrhage, and other peripheral vascular abnormalities. Their ability to polymerize upon contact with blood, provide permanent vessel occlusion, and support targeted embolization contributes to their adoption in interventional radiology procedures.

Application Insights

Based on applications, the venous applications (varicocele, PCS, varicose veins) segment led the market with the largest revenue share of 44.6% in 2025, driven by the increasing use of minimally invasive endovascular procedures for managing venous disorders. Liquid embolic agents support targeted vessel occlusion during embolization procedures, offering an alternative to more invasive surgical interventions. Growing clinical adoption of catheter-directed embolization for varicocele and pelvic congestion syndrome, along with the use of endovenous techniques for managing venous insufficiency, supports demand for embolic products.

The hypervascular tumors segment is expected to register significant growth in the peripheral liquid embolic agent market, driven by the increasing use of preoperative and therapeutic embolization to reduce tumor vascularity and control blood supply. Liquid embolic agents enable targeted occlusion of tumor-feeding vessels, supporting reduced intraoperative blood loss and improved surgical management of selected hypervascular tumors. Growing adoption of minimally invasive embolization procedures for peripheral vascular tumors, increasing availability of advanced catheter-based delivery systems, and improvements in embolic formulations are supporting segment expansion.

Regional Insights

North America dominated the peripheral liquid embolic agent market with the largest revenue share of 39.3% in 2025, due to the growing preference for minimally invasive endovascular procedures in the management of complex peripheral vascular conditions. The region has a well-developed healthcare infrastructure with widespread availability of advanced angiography systems, dedicated interventional radiology suites, and experienced vascular specialists, enabling greater utilization of liquid embolic technologies. Demand has been supported by the increasing number of embolization procedures performed for peripheral vascular hemorrhage, hypervascular tumors, peripheral vascular malformations (AVMs), peripheral aneurysms, pseudoaneurysms, Type II end leaks, and portal vein embolization (PVE) prior to liver resection.

U.S. Peripheral Liquid Embolic Agent Market Trends

The increasing prevalence of varicose veins in the U.S. is supporting demand for minimally invasive endovenous treatment options, including cyanoacrylate-based adhesive closure procedures. The growing patient population requiring treatment for chronic venous disorders, particularly among aging individuals and people with prolonged standing or sedentary lifestyles, is supporting the adoption of catheter-based interventions. Cyanoacrylate-based closure systems provide permanent occlusion of incompetent superficial veins through endovascular adhesive delivery, offering an alternative to conventional surgical approaches. Increasing clinical adoption of minimally invasive venous treatments and advancements in adhesive-based closure technologies are supporting demand for liquid embolic agents in peripheral venous applications.

"Varicose and spider veins tend to appear in people's 30s and 40s. It’s more common in women and among those who are on their feet a lot, including store clerks, nurses and doctors, restaurant workers, and manual laborers. Genetics plays a big role: if both parents have varicose veins, their children have roughly a 90% chance of having them too. - said Dr. Max Wohlauer, a University of Colorado School of Medicine associate professor of vascular surgery who treats patients at the UCHealth Cardiac and Vascular Center on the Anschutz Medical Campus."

According to the data published by Precision Medical Specialists in 2025, the following graph illustrates the prevalence of varicose veins among Americans aged 40-80 years.

In the U.S., peripheral arterial hemorrhage is a key application driving the peripheral liquid embolic agent market, supported by the increasing adoption of minimally invasive endovascular procedures to manage traumatic, iatrogenic, gastrointestinal, renal, pelvic, and visceral arterial bleeding. Hospitals are utilizing transcatheter arterial embolization as a preferred treatment approach because it enables rapid hemorrhage control while reducing procedural morbidity, blood loss, and recovery time compared with open surgical intervention. This has increased the use of liquid embolic agents in cases involving small, tortuous, or complex peripheral arteries where precise and durable vessel occlusion is required. Their ability to penetrate distal vasculature, provide permanent embolization, and achieve effective hemostasis independent of the patient's coagulation status makes them particularly valuable in trauma patients and individuals with coagulopathy.

Europe Peripheral Liquid Embolic Agent Market Trends

The Europe peripheral liquid embolic agent market is growing due to the increasing adoption of minimally invasive embolization procedures for peripheral vascular conditions, supported by the expansion of interventional radiology and vascular care infrastructure across the region. The rising burden of peripheral vascular disorders, including peripheral vascular malformations, aneurysms, hemorrhage, and venous disorders, is increasing the demand for advanced embolization technologies. Europe has a well-established network of specialized hospitals and interventional radiology centers that perform image-guided vascular procedures, supporting the clinical adoption of liquid embolic agents such as ethylene vinyl alcohol copolymer and cyanoacrylate-based agents.

In the UK, the availability of specialized vascular centers, established endovascular treatment pathways, and growing expertise among vascular specialists are supporting the adoption of embolization procedures to treat aneurysm-related complications. Improvements in vascular imaging and surveillance following EVAR are enabling earlier identification and management of Type II endoleaks, increasing the utilization of peripheral liquid embolic agents. The continued focus on reducing aneurysm-related complications and improving long-term outcomes after endovascular repair is expected to support the expanding role of liquid embolic agents in the management of aneurysms and Type II endoleaks across the UK.

According to data published by the National Vascular Registry in 2025, when aneurysms develop in the aorta, they most frequently occur below the arteries supplying the kidneys and are known as infra-renal AAAs. The NVR received information on 2,511 people who had an elective repair of an unruptured infra-renal AAA in 2024, which corresponds to an estimated case-ascertainment rate for the UK of 91% (for England = 91%; for Wales = >100%; for Scotland = 64%; for NI = 100%)

Source: National Vascular Registry 2025

In Germany, the increasing burden of Abdominal Aortic Aneurysms (AAAs) and the occurrence of Type II endoleaks after endovascular aneurysm repair (EVAR) are key factors driving growth in the peripheral liquid embolic agent market in Germany. AAA is more prevalent among the aging population, particularly in older men, leading to a higher number of patients requiring minimally invasive endovascular treatment. With the continued adoption of EVAR for AAA management, the need for effective treatment of post-procedural complications has increased. Type II endoleaks are among the most frequently observed complications following EVAR, resulting from persistent retrograde blood flow from collateral vessels, mainly lumbar arteries and the inferior mesenteric artery, into the excluded aneurysm sac.

Asia Pacific Peripheral Liquid Embolic Agent Market Trends

The Asia Pacific peripheral liquid embolic agent market is driven by the growing adoption of minimally invasive endovascular therapies and the continued expansion of interventional radiology services across the region. Rising incidences of peripheral vascular disorders, traumatic vascular injuries, gastrointestinal bleeding, hypervascular tumors, aneurysms, and peripheral vascular malformations are contributing to a higher volume of embolization procedures in clinical practice. Healthcare providers are investing in advanced angiography systems, hybrid operating rooms, and image-guided intervention capabilities, improving access to catheter-based embolization treatments. In addition, the increasing number of trained interventional radiologists, expansion of tertiary and specialty hospitals, and greater awareness of embolization as an effective alternative to open surgery are supporting the adoption of liquid embolic agents for peripheral applications.

The rising burden of varicose veins in Japan is driving growth in the peripheral liquid embolic agent market, driven by growing demand for minimally invasive venous treatment approaches. Varicose veins, primarily associated with chronic venous insufficiency and malfunctioning venous valves, are becoming an important vascular health concern due to the aging population and increasing need for effective symptom management. The shift from conventional surgical vein stripping toward minimally invasive endovascular procedures has increased the adoption of advanced venous closure technologies. Liquid embolic agents, particularly adhesive-based embolic materials, are gaining attention for enabling non-thermal vein occlusion through controlled delivery and reduced dependence on energy-based ablation techniques. The rising number of patients undergoing treatment for symptomatic varicose veins, along with increasing physician preference for minimally invasive procedures, is creating opportunities for peripheral liquid embolic agents in venous applications.

For instance, data published by Springer in 2026 and the 2024 National Clinical Database (NCD) annual report by the Japan Surgical Society indicate that 223,422 peripheral vascular surgical procedures were registered in the NCD in 2024, an increase of more than 2,700 cases compared with 2023. The procedure with the highest number in this category was endovascular treatment for extremity arteries.

In India, the increasing adoption of venous applications, including varicocele, pelvic congestion syndrome, and varicose veins, is driving growth in India's peripheral liquid embolic agent market by expanding the use of minimally invasive embolization procedures beyond arterial interventions. Varicocele treatment via embolization is gaining acceptance as an alternative to surgical approaches due to its minimally invasive nature, shorter recovery time, and selective occlusion of abnormal venous pathways. Pelvic congestion syndrome is receiving greater clinical attention as improved diagnostic imaging enables better identification of pelvic venous disorders and supports the use of endovascular embolization techniques for symptom management. The growing burden of chronic venous insufficiency and varicose veins, along with increasing preference for minimally invasive venous procedures, is encouraging vascular specialists and interventional radiologists to adopt advanced embolic technologies.

Latin America Peripheral Liquid Embolic Agent Market Trends

The peripheral liquid embolic agent market in Latin America is supported by the expanding adoption of minimally invasive endovascular procedures, improvements in interventional radiology infrastructure, and increasing demand for catheter-based treatments for peripheral vascular conditions. Growing diagnosis and treatment of venous disorders, peripheral arteriovenous malformations, vascular abnormalities, and hypervascular tumors are creating demand for embolization procedures across the region. Healthcare facilities in Colombia are expanding access to specialized vascular and interventional radiology services. Regulatory oversight by Colombia’s National Institute for Food and Drug Surveillance (INVIMA), under Decree 4725 of 2005, establishes requirements for medical device registration, marketing authorization, and post-market surveillance, supporting the regulated introduction of embolization technologies. Increasing preference for minimally invasive treatments that reduce surgical invasiveness, hospital stays, and recovery time is supporting the utilization of liquid embolic agents.

Middle East & Africa Peripheral Liquid Embolic Agent Market Trends

The Middle East and Africa (MEA) region is driving growth in the peripheral liquid embolic agent market through the expansion of endovascular treatment capabilities, the increasing availability of interventional radiology services, and rising demand for minimally invasive management of peripheral vascular conditions. The growing need for treatment of peripheral vascular malformations, arteriovenous malformations (AVMs), peripheral vascular hemorrhage, aneurysm-related complications, and venous disorders is encouraging the adoption of embolization techniques that provide targeted vessel occlusion. Healthcare infrastructure development, including the establishment of advanced hospitals, catheterization laboratories, and image-guided intervention units, is improving access to complex vascular procedures across the region. Regulatory oversight by authorities such as the Saudi Food and Drug Authority (SFDA), which evaluates medical devices and grants marketing authorization before commercialization in Saudi Arabia, provides a defined regulatory pathway for the introduction of liquid embolic products.

Key Peripheral Liquid Embolic Agent Company Insights

Key peripheral liquid embolic agent companies are focusing on developing and supplying advanced embolic formulations and delivery systems for minimally invasive peripheral vascular procedures. Companies are prioritizing improvements in embolic composition, viscosity, radiopacity, polymerization characteristics, and catheter compatibility to support controlled delivery and effective vessel occlusion. The development of cyanoacrylate-based adhesives and ethylene-vinyl alcohol copolymer (EVOH)-based agents is expanding product availability across different peripheral vascular indications. Manufacturers are also investing in formulation optimization, delivery-system compatibility, and clinical research to improve procedural precision, product performance, and treatment outcomes in peripheral embolization procedures.

Key Peripheral Liquid Embolic Agent Companies:

The following key companies have been profiled for this study on the peripheral liquid embolic agent

• Medtronic

• BALT Group

• Terumo Medical Corporation (MicroVention)

• GEM S.r.l. (H.B. Fuller Company)

• Qmedics

• B. Braun SE

• NeuroSafe Medical Co., Ltd.

• Boston Scientific Corporation

• BlackSwan Vascular (Sirtex Medical)

• Instylla, Inc.

• Johnson & Johnson

• Others

 

Recent Developments

• In January 2026, Instylla announced the completion of the first commercial procedure using the Embrace Hydrogel Embolic System, performed by Dr. Ripal Gandhi. The milestone marked the beginning of commercial use of the hydrogel-based liquid embolic system for peripheral vascular embolization.

• In August 2025, Instylla received U.S. FDA Premarket Approval (PMA) for its flagship Embrace Hydrogel Embolic System (HES). The device was approved for the embolization of hypervascular tumors in peripheral arteries ≤5 mm, marking a significant regulatory milestone for Instylla’s peripheral liquid embolic technology.

• In June 2025, BALT acquired its Canadian distributor, Yocan Medical Systems Ltd., which began operating as Balt Canada Ltd. The acquisition established Balt’s direct presence in Canada and supported its global expansion strategy. Following the acquisition, Balt expanded its international footprint to 16 sites worldwide.

Peripheral Liquid Embolic Agent Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends across each sub-segment from 2021 to 2036. For this study, Grand View Research has segmented the global peripheral liquid embolic agent market report based on product type, application, and region.

• Peripheral Liquid Embolic Agent Market Product Type Outlook (Revenue, USD Million, 2021 - 2036)

  • Ethylene Vinyl Alcohol Copolymer (EVOH)

  • Cyanoacrylates / Tissue Glues

    • n-Butyl Cyanoacrylate (n-BCA)

    • n-Hexyl Cyanoacrylate (n-HCA)

  • Others

• Peripheral Liquid Embolic Agent Market Application Outlook (Revenue, USD Million, 2021 - 2036)

  • Peripheral Vascular Hemorrhage

  • Hypervascular Tumors

  • Peripheral Vascular Malformations / AVMs

  • Aneurysms / Pseudoaneurysms

  • Type II Endoleaks

  • Portal Vein Embolization (PVE)

  • Venous Applications (varicocele, PCS, varicose veins)

  • Other Peripheral Embolization Applications

• Regional Outlook (Revenue, USD Million, 2021 - 2036)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Rest of Europe

  • Asia Pacific

    • Japan

    • India

    • Rest of Asia Pacific

  • Latin America

    • Colombia

  • Middle East & Africa

    • South Africa

    • Middle East

    • North Africa

Research Methodology

The peripheral liquid embolic agent market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each peripheral liquid embolic agent market segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations